Tachyon Ventures

Tachyon Ventures is a specialist investment firm focused on biotechnology, backing approaches to understanding biology and treating disease across the United States and Europe. The firm deploys capital through two channels: direct investments in early-stage companies and the acquisition of limited partner interests in biotech venture funds, with the latter concentrating on portfolios of late-stage companies.

Direct US activity spans pre-seed through Series A. In Europe, the firm invests at early stage, including ventures emerging from academic research. Technical areas covered include therapeutic targets, molecular design and delivery, diagnostics, bioengineering, gene therapy, RNA medicines, drug discovery and engineered tissues. Target companies are selected on the basis of differentiated biology, technology or proprietary data.

The firm describes its approach as science-native, assessing opportunities through the underlying science rather than market framing alone. Its team combines experience in scientific research, early-stage investing, company building and venture secondaries, and works across the US and Europe. Founding year, team size and fund scale are not disclosed.